WeVote
Log In

Bill

Bill

LC 2294

Allowing sale and purchase of ivermectin without prescription

2025 Regular Session

LC 2294 would allow selling ivermectin without a prescription, expanding access but risking unsupervised use; the draft died in process.

(LC) Draft Died in Process
#professionsandoccupationso-z #healthcareservices
0
WeVote Research Nonpartisan
Bill Summary · LC 2294

Summary of LC 2294: Allowing sale and purchase of ivermectin without prescription

Overview

  • Bill number: LC 2294
  • Title: Allowing sale and purchase of ivermectin without prescription
  • Subject: Health Care Services; Professions and Occupations O-Z
  • Introduction date: December 8, 2024
  • Status: Draft; Died in Process (LC)

This bill proposes allowing the sale and purchase of ivermectin without a prescription. The available information does not include the full text of the bill, so specific provisions beyond the overarching goal are not detailed here.

Purpose and Intent

  • The primary aim, as reflected in the title, is to remove the prescription requirement for ivermectin, enabling its sale and purchase without a formal medical prescription.
  • The bill’s intent, based on its title, appears to focus on increasing access to ivermectin by removing the prescription barrier. No explicit rationale or supporting findings are provided in the information available.

Key Provisions (What is Known)

  • The bill would authorize the sale and purchase of ivermectin without a prescription.
  • Specific mechanisms, such as where ivermectin could be sold (pharmacies, retail outlets, online platforms), dispensing standards, labeling, age restrictions, or pharmacist oversight, are not described in the provided summary.
  • No details are available on safeties, monitoring, or enforcement provisions within the bill text.

Note: The exact text of LC 2294 has not been included in the provided materials, so the above reflects the bill’s stated objective and the absence of additional provision details in this summary.

Affected Parties

  • General public/consumers: Potential greater direct access to ivermectin without needing a prescription.
  • Pharmacies and retailers: Would need to adjust dispensing practices if the bill becomes law.
  • Healthcare professionals and prescribers: May experience changes in prescribing workflows and patient access patterns.
  • Regulators and state agencies: Responsible for implementing any new dispensing rules and monitoring safety/compliance.

Procedural Timeline and Status

  • 2024-12-08: Draft On Hold; Drafter Assigned
  • 2025-02-11: Draft Taken Off Hold
  • 2025-02-13: Draft in Legal Review
  • 2025-05-22: Draft Died in Process

Current status indicates the draft ultimately did not advance in the legislative process.

Potential Impacts and Considerations

  • Accessibility: Increased ease of obtaining ivermectin without prescription.
  • Safety and misuse concerns: Potential risks from unsupervised use, incorrect dosing, drug interactions, and delayed medical evaluation for adverse effects.
  • Public health implications: Balancing improved access with appropriate use and monitoring of adverse events.
  • Regulatory framework: Unclear from available information; would depend on text-specific provisions such as labeling, age restrictions, or dispensing controls.
  • Legal certainty: With the bill died in process, no legal changes are enacted; however, the concept may reappear in future amendments or new bills.

Next Steps for Readers

  • If you are tracking this bill for professional or advocacy reasons, monitor legislative trackers for any future reintroduction or amendments.
  • Review the full bill text when available to understand exact provisions, enforcement mechanisms, penalties, and any companion measures (e.g., pharmacist requirements, reporting).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.